Swedish Orphan Biovitrum Net Cash Flow 2019-2025 | BIOVF

Swedish Orphan Biovitrum net cash flow for the twelve months ending June 30, 2025 was $-0.029B, a 80.97% decline year-over-year.

  • Swedish Orphan Biovitrum annual net cash flow for 2024 was $0.022B, a 151.81% decline from 2023.
  • Swedish Orphan Biovitrum annual net cash flow for 2023 was $-0.043B, a 237.61% decline from 2022.
  • Swedish Orphan Biovitrum annual net cash flow for 2022 was $0.031B, a 58.1% decline from 2021.

Swedish Orphan Biovitrum Net Cash Flow 2019-2025 | BIOVF

  • Swedish Orphan Biovitrum annual net cash flow for 2024 was $0.022B, a 151.81% decline from 2023.
  • Swedish Orphan Biovitrum annual net cash flow for 2023 was $-0.043B, a 237.61% decline from 2022.
  • Swedish Orphan Biovitrum annual net cash flow for 2022 was $0.031B, a 58.1% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.1B
Amgen (AMGN)$155.2B
Gilead Sciences (GILD)$148.2B
Vertex Pharmaceuticals (VRTX)$94B
Bristol Myers Squibb (BMY)$93.5B
CSL (CSLLY)$82.7B
GSK (GSK)$77.1B
Regeneron Pharmaceuticals (REGN)$59.7B
Alnylam Pharmaceuticals (ALNY)$57.5B
Argenex SE (ARGX)$40.5B
BioNTech SE (BNTX)$26.8B
Insmed (INSM)$23.2B
Royalty Pharma (RPRX)$21.1B
Biogen (BIIB)$19.2B
Incyte (INCY)$15.3B
Illumina (ILMN)$14.5B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.7B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.7B
Moderna (MRNA)$10.2B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$7.9B
Roivant Sciences (ROIV)$7.8B
Exact Sciences (EXAS)$7.8B
Halozyme Therapeutics (HALO)$7.8B
Anbio Biotechnology (NNNN)$7.3B